$1B Credit Facility Bolsters Neurocrine's Liquidity Post-Soleno Acquisition
NBIX sits 34% above its 52-week low of $117.59.
Summary
Neurocrine Biosciences has secured a new five-year $1.0 billion secured revolving credit facility, with $600 million drawn at closing. This financing event provides significant liquidity and financial flexibility for the company. While the completion of the Soleno Therapeutics acquisition was previously reported via an 8-K filing and news on May 18th, the details of this new credit facility are fresh information. This facility likely supports the company's capital structure following the $2.9 billion cash acquisition of Soleno, which was initially announced with Q1 2026 results. Traders should note the enhanced financial capacity and watch for how this capital is deployed and its impact on future growth initiatives.
At the time of this announcement, NBIX was trading at $157.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.8B. The 52-week trading range was $117.59 to $162.39. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.